SCHEDULE: Vanguard Reports 7.49% Stake in Bristol-Myers Squibb

Vanguard Capital Management disclosed a beneficial ownership of 153,108,018 shares, representing 7.49% of Bristol-Myers Squibb's common stock as of March 31, 2026.

Summary

• Vanguard Capital Management, along with its affiliates, has reported a significant ownership stake in Bristol-Myers Squibb Co.
• The filing indicates beneficial ownership of 153,108,018 shares of common stock.
• This holding represents 7.49% of the total class of securities.
• Vanguard Capital Management exercises sole dispositive power over these shares.
• The reporting date for this ownership is March 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports existing passive ownership by a major institutional investor and does not contain operational or financial performance updates for Bristol-Myers Squibb.

Positives

• Vanguard's substantial investment suggests confidence in Bristol-Myers Squibb's long-term prospects.
• A large institutional holder like Vanguard can provide stability and credibility to the company's stock.

Negatives

• The filing is a Schedule 13G, indicating passive investment, which means Vanguard is not seeking to influence control of the company. This could imply a lack of active engagement in strategic decisions.

Risks

• While Vanguard's investment is passive, any significant shift in their holdings could impact the stock price.
• The filing does not detail specific risks related to Bristol-Myers Squibb's business operations, but rather focuses on ownership.

Future Outlook

This filing is a snapshot of ownership as of a specific date and does not contain forward-looking statements or guidance from Bristol-Myers Squibb. Vanguard's future outlook is implied by its passive investment strategy.

Management Comments

• "In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd."
• "This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power."
• "This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that large institutional holdings, as reported in Schedule 13G filings, are common in the pharmaceutical and biotechnology sectors, reflecting significant investor interest in companies like Bristol-Myers Squibb. Vanguard's passive stake is typical for a major asset manager.

Stakeholder Impact

• Shareholders: The filing confirms a significant passive stake by a major institutional investor, which can be seen as a vote of confidence, potentially stabilizing the stock price.
• Vanguard Clients: Clients invested in Vanguard funds benefit from the diversification and potential returns associated with this holding.
• Bristol-Myers Squibb Management: While Vanguard's stake is passive, its size means the company is aware of its significant institutional ownership.

Next Steps

• Vanguard will continue to hold its shares in Bristol-Myers Squibb as part of its investment portfolio.
• Bristol-Myers Squibb will continue its operations and report its financial and operational results in subsequent filings.

Key Dates

Keywords

Bristol-Myers Squibb, Vanguard, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Management